SAM..from the ANP announcement a week ago...
The Company’s IND application for a Phase IIb trial in 195 MS patients is on track for submission to the US Food and Drug Administration (FDA) by April 2017. Monkey plasma samples from a previously conducted animal toxicology study have been assayed and the pharmacokinetic data will soon be available for inclusion in the IND application. Following the IND submission, the Company must wait 30 calendar days for the FDA to review the submission.
immature, page-6
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 13.0¢ | $378.0K | 2.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 516956 | 4 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |